

**Table 3: Geometric mean antibody titres before and 7 and 21 days after vaccination with trivalent influenza vaccine in subjects treated with placebo or *Chlorella pyrenoidosa* extract (CPE)\***

Influenza strain and treatment	Geometric mean antibody titre (and 95% CI), reciprocal dilution		
	Day of vaccination	7 days	21 days
<b>Age 50–55 yr</b>			
<i>A/New Caledonia</i>			
Placebo	23.0 (13.7–38.6)	29.0 (16.9–49.7)	43.2 (27.1–69.0)
200 mg CPE	23.0 (12.1–43.8)	47.8 (32.3–70.9)	84.3 (55.3–129)
400 mg CPE	33.4 (17.1–65.1)	57.6 (29.5–112)	84.4 (46.7–152)†
<i>A/Panama</i>			
Placebo	28.6 (15.1–54.1)	39.9 (20.5–77.8)	65.9 (37.7–115)
200 mg CPE	16.0 (9.17–28.0)	26.6 (14.5–48.6)	57.4 (40.5–81.3)
400 mg CPE	33.2 (15.3–72.3)	64.5 (33.5–124)	87.9 (45.2–171)
<i>B/Yamanashi</i>			
Placebo	11.4 (7.90–16.5)	14.4 (9.28–22.2)	29.6 (16.3–44.6)
200 mg CPE	12.7 (7.25–22.1)	15.9 (8.82–28.8)	25.3 (14.3–44.8)
400 mg CPE	15.7 (8.90–27.9)	30.1 (17.4–52.1)‡	39.5 (23.5–66.5)
<b>Age &gt; 55 yr</b>			
<i>A/New Caledonia</i>			
Placebo	30.6 (16.6–56.5)	51.8 (28.3–94.8)	74.0 (39.9–137)
200 mg CPE	26.8 (16.5–43.5)	42.1 (26.6–66.8)	70.1 (43.2–114)
400 mg CPE	21.3 (12.3–36.7)	36.7 (21.4–63.0)	46.7 (25.6–85.4)
<i>A/Panama</i>			
Placebo	35.1 (19.6–62.7)	61.6 (38.2–99.3)	99.4 (65.0–152)
200 mg CPE	37.1 (25.3–54.4)	56.2 (39.6–79.6)	84.7 (61.7–116)
400 mg CPE	53.4 (31.1–91.6)	74.5 (44.4–125)	98.4 (57.1–170)
<i>B/Yamanashi</i>			
Placebo	13.1 (9.06–18.9)	18.8 (12.3–28.9)	25.8 (16.5–40.3)
200 mg CPE	9.43 (6.79–13.1)	13.2 (9.51–18.4)	20.0 (13.8–28.9)
400 mg CPE	11.2 (7.30–17.1)	16.3 (10.7–25.0)	19.2 (12.5–29.5)

Note: CI = confidence interval.

\*The point data in this table are presented graphically in Fig. 2.

†Significantly different from before vaccination ( $p = 0.047$ ).

‡Significantly different from before vaccination ( $p = 0.034$ ).